Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 10, 2026
Why Is Fermi Inc. (FRMI) Stock Down -16% Today?

Why Is Fermi Inc. (FRMI) Stock Down -16% Today?

Key Takeaways

  • Shares of Fermi Inc. are down roughly 16% in premarket trading following news of a $375 million convertible senior notes offering.
  • The primary catalyst is dilution concern tied to the upsized convertible debt sale, which offers conversion protection only up to $14.64 per share.
  • Secondary drivers include ongoing investor skepticism around Fermi's pre-revenue status and its heavy cash-burn profile as it builds out its Texas data center campus.
  • The move adds to a volatile 2026 for Fermi, which has repeatedly swung double digits on tenant, leadership, and financing news.
  • Broader AI-infrastructure and data-center REIT sentiment remains a backdrop, though this move appears company-specific rather than sector-wide.
  • Traders are watching for details on note pricing, use of proceeds, and any update on tenant negotiations for Project Matador.

Opening Summary

Fermi Inc. (FRMI) is a Dallas-based real estate investment trust developing large-scale, grid-independent power and data center infrastructure for artificial intelligence workloads, centered on its Project Matador campus in Amarillo, Texas. The stock closed the prior session at $7.36 and is indicated down approximately 16% in premarket trading Friday, putting shares near the $6.20 level. The decline follows the company's announcement of an upsized $375 million convertible senior notes offering, priced with dilution protection only up to $14.64 per share. Markets are reacting primarily to dilution concerns tied to the size and structure of this capital raise.

Convertible Notes Offering and Dilution Concerns

Fermi priced an upsized offering of $375 million in convertible senior notes late Wednesday, with the "dilution offset" provision protecting shareholders only up to $14.64 per share—well above the stock's recent trading range. Convertible debt raises of this kind typically pressure share prices because they signal future share issuance risk and can be interpreted as a sign management needed capital sooner than the market expected. Similar convertible offerings from other capital-intensive infrastructure names have historically triggered comparable double-digit selloffs when investors price in the potential increase in share count.

Ongoing Cash Burn and Pre-Revenue Status

Fermi remains a pre-revenue company with no confirmed tenant lease for Project Matador, a persistent overhang that has weighed on the stock throughout 2026. The company has been burning cash at a rate described by analysts as roughly negative $1.05 billion in free cash flow annually, with no near-term profitability path, which amplifies sensitivity to any new financing news. Stifel recently cut its price target on the stock from $29 to $17, citing continued contract delays with prospective tenants.

Market Context and Trading Activity

Fermi has been one of the most volatile names on Nasdaq since its October 2025 IPO, having swung by double-digit percentages on multiple occasions this year tied to tenant negotiations, executive departures, and financing announcements. The stock is down more than 80% from its IPO price of $21 and remains far below its 52-week high near $37. This premarket move appears specific to Fermi's balance sheet news rather than reflecting a broader decline across data-center REITs or AI infrastructure peers.

Trending AI Robots

For traders tracking momentum in volatile names like Fermi, Tickeron's Trending AI Robots page curates a selection of algorithmic trading bots that are currently performing strongest under prevailing market conditions. Tickeron runs hundreds of AI-driven trading bots across thousands of tickers, but only a select group of top performers is featured in this section at any given time. These bots differ by trading strategy, timeframe, historical performance metrics, and the specific symbols they track. Investors interested in systematic, data-driven approaches to volatile stocks may find it useful to review the Trending AI Robots page for insight into current algorithmic signals and performance trends.

What Comes Next for FRMI

Investors will be watching for further disclosure on how proceeds from the $375 million notes offering will be deployed toward Project Matador's buildout, along with any progress on securing a confirmed tenant lease. Analyst commentary following the offering, including potential further price target revisions, is likely in the coming sessions. Key risks include continued cash burn, execution risk on the 17-gigawatt power buildout timeline, and any fresh developments related to past leadership disputes with former CEO Toby Neugebauer. No specific earnings date or major data release has been confirmed for the immediate term.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: FRMI

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


FRMI sees its Stochastic Oscillator recovers from oversold territory

On August 05, 2026, the Stochastic Oscillator for FRMI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 7 instances where the indicator left the oversold zone. In of the 7 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where FRMI advanced for three days, in of 39 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FRMI as a result. In of 11 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FRMI turned negative on July 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 4 similar instances when the indicator turned negative. In of the 4 cases the stock turned lower in the days that followed. This puts the odds of success at .

FRMI moved below its 50-day moving average on July 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FRMI crossed bearishly below the 50-day moving average on July 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 1 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FRMI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FRMI entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.678) is normal, around the industry mean (103.703). P/E Ratio (0.000) is within average values for comparable stocks, (61.085). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.220). FRMI's Dividend Yield (0.000) is considerably lower than the industry average of (0.045). FRMI's P/S Ratio (0.000) is slightly lower than the industry average of (6.689).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FRMI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FRMI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

Notable companies

The most notable companies in this group are American Tower Corp (NYSE:AMT).

Industry description

Companies belonging to the specialty telecommunications sector provide voice and data transmission via a single method, such as fixed lines, digital subscriber lines (DSL), wireless technology, the internet or competitive local exchange carriers. Telefonica, Liberty Broadband Corp., and Zayo Group Holdings, Inc. are some of the big specialty telecom companies in the U.S.

Market Cap

The average market capitalization across the Specialty Telecommunications Industry is 21.88B. The market cap for tickers in the group ranges from 2.04K to 104.22B. EQIX holds the highest valuation in this group at 104.22B. The lowest valued company is CWTC at 2.04K.

High and low price notable news

The average weekly price growth across all stocks in the Specialty Telecommunications Industry was -0%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 5%. WY experienced the highest price growth at 8%, while FRMI experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the Specialty Telecommunications Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was 17% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 68
Price Growth Rating: 51
SMR Rating: 69
Profit Risk Rating: 76
Seasonality Score: -25 (-100 ... +100)
View a ticker or compare two or three
FRMI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry SpecialtyTelecommunications

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.